--- title: "What Is a GLP-1 Drug, and Why Has It Reshaped Healthcare Investing?" description: "A single class of medicines, the GLP-1 drugs behind Ozempic, Wegovy, Mounjaro and Zepbound, has turned two drugmakers into among the most valuable companies on earth and rippled far beyond health care. Here is what these drugs are, in plain English, and why investors cannot stop talking about them." category: "Economy" category_url: https://boursel.com/category/economy author: "Rafael Ortiz" published: 2026-07-06T22:37:50.000Z updated: 2026-07-06T22:37:50.000Z canonical: https://boursel.com/article/what-is-a-glp-1-drug-and-why-has-it-reshaped-healthcare-investing tags: ["glp-1", "novo-nordisk", "eli-lilly", "healthcare", "pharma", "obesity"] --- # What Is a GLP-1 Drug, and Why Has It Reshaped Healthcare Investing? A single class of medicines, the GLP-1 drugs behind Ozempic, Wegovy, Mounjaro and Zepbound, has turned two drugmakers into among the most valuable companies on earth and rippled far beyond health care. Here is what these drugs are, in plain English, and why investors cannot stop talking about them. Few developments have moved markets in recent years like a class of drugs originally designed for diabetes. GLP-1 medicines have become a household topic, a stock-market obsession and a force reshaping industries far from the pharmacy. Here is what they actually are, and why they matter to investors. ## The science, in plain English "GLP-1" is short for glucagon-like peptide-1, a hormone the body releases after eating. It does several useful things: it prompts the pancreas to release insulin when blood sugar rises, tempers the liver's release of glucose, and signals to the brain that you are full. GLP-1 drugs are lab-made molecules that mimic that hormone, [as medical reviews explain](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11408715/), amplifying the body's own appetite-control system. In practice, they slow how quickly the stomach empties, so people feel satisfied with less food, and they dull cravings by acting on appetite centers in the brain. For people with type 2 diabetes, the blood-sugar control is the point; for people with obesity, the appetite effect is. The medicines come as weekly injections and, increasingly, as daily pills. ## The two companies that dominate Two drugmakers tower over this market. **Novo Nordisk**, of Denmark, makes semaglutide, sold as Ozempic for diabetes and Wegovy for weight loss. It effectively created the modern obesity-drug category. **Eli Lilly**, of the United States, makes tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss. Lilly's drug has generally produced greater average weight loss in trials, and the company has been growing quickly: its filings show Mounjaro and Zepbound sales rising sharply in 2025, [according to its results](https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000008/q425lillysalesandearningsp.htm). Both firms are now racing to add oral versions to their injectable franchises. ## Why it reshaped healthcare investing The reason the financial world fixated on these drugs is the sheer size of the potential market. Hundreds of millions of people worldwide live with obesity or type 2 diabetes, and before GLP-1s no medicine reliably delivered large, sustained weight loss. Analysts at Morgan Stanley have estimated the market for these drugs could roughly double to about $190 billion by 2035, [in one widely cited projection](https://www.morganstanley.com/insights/articles/glp1-weight-loss-market-may-double-190-billion-2035). That prospect transformed the two leaders. Novo Nordisk and Eli Lilly became among the most valuable companies in the world on the strength of these franchises, with Lilly's market value climbing especially steeply. Unlike many market manias, this one was backed by real, fast-growing revenue rather than promise alone. ## The investment debate The bull case is straightforward: a vast, under-treated population and two companies with a head start. The debate is over what could go wrong, or simply change. **Pills versus injections.** Oral versions are easier to start and distribute and could widen the market, but injectables still tend to show stronger results. Which format wins, and who leads in each, is unsettled. **Patents and eventual competition.** These drugs enjoy patent protection for years yet, but not forever. When key patents lapse, cheaper generic or "biosimilar" competition typically drives prices down hard. That is a distant cliff, not a near-term one, but it shapes how investors value the long-run profit stream. **Pricing and coverage.** How much health systems, insurers and employers will pay, and for whom, is central. Broader insurance coverage could swell demand while squeezing the price per prescription, a tension that cuts both ways for profits. **Ripple effects.** Because these drugs change how much people eat, analysts have speculated about knock-on effects for food and beverage companies, restaurants and other consumer businesses. These second-order predictions are uncertain and easy to overstate, but they explain why the drugs are discussed well beyond the health-care aisle. ## The bottom line A GLP-1 drug is, at its core, a hormone mimic that curbs appetite and steadies blood sugar. What makes it a market story is scale: a treatment for conditions affecting a large share of the world's population, controlled largely by two companies, with the technology shifting from injections toward pills. For investors, the appeal and the risk are the same thing, an enormous market whose eventual size, pricing and competitive shape are still being decided. This article is informational and not investment or medical advice. ## Sources - [GLP-1 weight-loss market may double to $190 billion by 2035](https://www.morganstanley.com/insights/articles/glp1-weight-loss-market-may-double-190-billion-2035) - [Glucagon-like peptide-1 receptor: mechanisms and advances in therapy](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11408715/) - [Eli Lilly Q4 2025 sales and earnings](https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000008/q425lillysalesandearningsp.htm)